Absolute Markets Insights offers its latest published report ‘Ankylosing Spondylitis Market by Product (Integrated Software, Standalone Software); by Drug Type (Nonsteroidal Anti-Inflammatory Drugs, TNF blockers, Immunosuppressive Drugs, Anti-Inflammatory Drugs, Steroids, JAK Inhibitors, Others (IL-17 Inhibitors); by Application (Juveniles, Adults); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America)) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026’. The author of the report analyzed that the global ankylosing spondylitis market accounted for US$ 5.34 Bn in 2017. Ankylosing spondylitis (AS) is also known as a type of arthritis that affects the spine part of the human body. Its symptoms are stiffness and pain from the neck down to the lower back. The spine's bones (vertebrae) fuse together, which causes rigid spine. Some of the treatments of the AS is early diagnosis and treatment to manage control pain and stiffness to reduce significant deformity. Ankylosing spondylitis is common in people with age between 17 to 35 years. There is no specific cause for this disease, but several risk factors such as sex, age and heredity can affect in development of AS. Some of the symptoms of ankylosing spondylitis seen in the adult category are lack of appetite, stooped posture, body aches, problems in inhaling deeply, and anemia among others. 

Purchase the complete report titled “Ankylosing Spondylitis Market – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026” at https://www.absolutemarketsinsights.com/reports/Ankylosing-Spondylitis-Market-2018-2026-123

Many research organizations and academic institutes are investing heavily in order to find a cure for ankylosing spondylitis. In order to encourage the research activities for diagnosis and treatment, the Spondylitis Association of America (SAA) offers research grant up to US$ 20,000. The organization is taking efforts in order to provide effective treatment options, improved quality of life and care management in ankylosing spondylitis (AS). As a part of their mission, in 2018 the organization granted research study on Microbiome of Offspring in Ankylosing Spondylitis (MOSAS). The group is awarded US$ 20,000 to continue their research studies.

Another study which is being conducted by Novartis Pharmaceuticals where they working to estimate the clinical difference between 300 mg and 150 mg of Secukinumab in patients with Ankylosing Spondylitis. This clinical trial is currently in phase 4 and the estimated completion date for this study is May 12, 2020.

Nonsteroid anti-inflammatory drugs (NSAIDs) can create several side effects in cardiovascular and gastrointestinal system. These drugs can reduce the protective mucus in stomach which can lead to stomach irritation. Over time, this can lead to gastritis, heartburn and ulcers in some cases. In patients with a history of heart diseases, NSAIDs can increase the risk of heart attack.

Adults Accounts for Largest Market Share in Application Segment

Ankylosing spondylitis can be seen in both young and old people. Though doctors are not aware of exact cause of AS, they have identified several risk factors such as genetics, family history, gender and age. As per the reports of Spondylitis Association of America, eighty percent of people get affected by ankylosing spondylitis before age of 30. Adults in this segment accounted for US$ 3.52 Bn in 2017.

North America Accounted for Largest Market Share

It has been reported that, the mean prevalence of ankylosing spondylitis per 10,000 people in North America region was found to be 31.9. It is highest amongst all the five regions. In the United States, 0.2% to 0.5% people are affected with ankylosing spondylitis.

Competitive Landscape

Key participants of global ankylosing spondylitis market are AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.

 Ankylosing Spondylitis Market - By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs
• TNF blockers
• Immunosuppressive Drugs
• Anti-Inflammatory Drugs
• Steroids
• JAK Inhibitors
• Others (IL-17 Inhibitors)

 Ankylosing Spondylitis Market - By Application

• Juveniles
• Adults
•  Ankylosing Spondylitis Market – By Region
  • North America
    • U.S.
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
    • Middle East and Africa
  • GCC Countries
    • Southern Africa
    • Rest of Middle East and Africa
  • Latin America
    • Brazil
    • Rest of Latin America